Summary
Twelve elderly non-insulin dependent diabetic patients took part in a double-blind, cross-over, randomized study comparing simvastatin 30 mg/day and placebo. Each treatment period lasted 3 weeks and was separated by a 3 week wash-out period. At the end of each treatment period all subjects underwent in randomized order an oral glucose tolerance test (OGTT; 75 g) and an euglycaemic hyperinsulinaemic (50 mU/kg·h) glucose clamp.
Simvastatin compared to placebo significantly reduced plasma total cholesterol (7.9 vs 5.3 mmol·l−1), LDL-cholesterol (7.2 vs 4.3 mmol·l−1), triglycerides (2.9 vs 2.1 mmol·l−1), free fatty acids (1106 vs 818 mmol−1) and glucose (7.4 vs 6.6 mmol·l−1) levels.
After simvastatin, and in the last 60 min of the glucose clamp, there was an improvement in the action of insulin as demonstrated by stronger inhibition of hepatic glucose output (2.7 vs 5.2 μmol·kg−1·min−1) and stimulation both of the glucose disappearance rate (26.3 vs 19.5 μmol·kg−1·min−1) and glucose metabolic clearance rate (4.3 vs 3.6 ml·kg−1·min−1).
The changes in glucose turnover parameters were significantly correlated with basal plasma free fatty acids and were independent of plasma glucoregulatory hormones. In conclusion, simvastatin seems to exert beneficial effects both on lipid and glucose metabolism.
Similar content being viewed by others
References
Kannel WB, Dawber TR, Kagon A, Revostikie N, Stokies J (1961) Factors of risk in the development of coronary heart disease: six years follow-up experience: the Framingham study. Ann Intern Med 55: 33–39
American Diabetes Association (1989) Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12: 573–579
Walker JF (1988) HMG-CoA reductase inhibitors. Current clinical experience. Drugs 36 [Suppl 3]: 83–86
Slater EE, MacDonald JS (1988) Mechanism of action and biological profile of HMG-CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 [Suppl 3]: 77–82
Kobayashi M, Ishida F, Takahashi T, Tagucki K, Watanabe K, Ohmura I, Kamei T (1989) Preventive effect of MK-733 (simvastatin) on inhibitors of HMG-CoA reductase, on hypercholesterolaemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol 49: 125–133
Saku K, Sasaki J, Arakawa K (1989) Low dose of simvastatin (MK-733) on serum lipids, lipoproteins and apolipoproteins in patients with hypocholesterolaemia. Clin Ther 11: 247–257
De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223
Paolisso G, Giugliano D, Scheen AJ, Franchimont P, D'Onofrio P, Lefebvre PJ (1987) Primary role of glucagon in the effect of Beta-endorphin on glucose homeostasis in normal men. Acta Endocrinol (Kbh) 195: 161–169
Prado M de, Zurcker G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within fentomole range. Life Sci 19: 1161–1167
Paolisso G, Sgambato S, Gentile S, Memoli P, Varricchio M, D'Onofrio F (1988) Adavantageous metabolic effects of pulsatile insulin delivery in non-insulin dependent diabetic subjects. J Clin Endocrinol Metabol 67: 1005–1010
Paolisso G, Scheen AJ, Luyckx AS, Lefebvre PJ (1987) Pulsatile hyperglucagonemia fails to increase hepatic glucose production in normal man. Am J Physiol 252: E1–7
Steele R (1959) Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420–430
Bagdade JD, Porte D Jr, Bierman EL (1967) Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med 276: 427–433
Brunzell JD, Porte D Jr, Bierman EL (1975) Reversible abnormalities in post-heparin lipolytic activity during the late phase of release in diabetes mellitus (post-heparin lypolitic activity in diabetes) Metabolism 24: 1123–1137
Fronzo RA de (1988) The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687
Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595–1607
Garg A, Grundy SM (1988) Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 318: 81–86
Garg A, Grundy SM (1989) Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 38: 364–372
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Paolisso, G., Sgambato, S., De Riu, S. et al. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol 40, 27–31 (1991). https://doi.org/10.1007/BF00315135
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315135